Vivimed acquires Uquifa for $ 55 million

02 Dec 2011 Evaluate

Hyderabad-based Vivimed Labs has acquired Uquifa, manufacturer of active pharma ingredients (APIs) and intermediates with operations in Spain and Mexico, for a consideration of $ 55 million. In a move to bring in strategic growth into its product mix and expand the footprint in Europe and the Americas, the company has taken a measured stride with the acquisition of Uquifa Spain and Uquifa Mexico. The investment consideration of $ 55 million is paid by equity infusion of $ 20 million, debt financing of $ 25 million and the balance of $ 10 million by way of deferred payment. Uquifa will become the active pharmaceutical ingredient (API) division of the Vivimed group.

The acquisition would strengthen the company's current position in pharma APIs and intermediates while significantly improving the cost competitiveness of Uquifa. Uquifa sells in over 70 countries and has over 150 active DMFs filed and 20 COS approved. The company has a net assets of $ 65 million and gross assets of $ 100 million as of this June. 

Vivimed Labs Share Price

17.63 -0.92 (-4.96%)
31-Dec-2025 14:16 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.00
Dr. Reddys Lab 1270.00
Cipla 1506.65
Zydus Lifesciences 913.10
Lupin 2110.40
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×